2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity

Science Translational Medicine

Volumn 9, Issue 375, 2017, Pages

  Sulkowski, Parker L ^a   Corso, Christopher D ^a   Robinson, Nathaniel D ^a   Scanlon, Susan E ^a   Purshouse, Karin R ^a   Bai, Hanwen ^a   Liu, Yanfeng ^a   Sundaram, Ranjini K ^a   Hegan, Denise C ^a   Fons, Nathan R ^a   Breuer, Gregory A ^a   Song, Yuanbin ^a   Mishra Gorur, Ketu ^a   De Feyter, Henk M ^a   De Graaf, Robin A ^a   Surovtseva, Yulia V ^b   Kachman, Maureen ^c   Halene, Stephanie ^a   Günel, Murat ^a   Glazer, Peter M ^a   Bindra, Ranjit S ^a   more..

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; OLAPARIB; ALPHA-HYDROXYGLUTARATE; GLUTARIC ACID DERIVATIVE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

ACUTE MYELOID LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DNA REPAIR; DRUG EFFICACY; DRUG SENSITIVITY; ENANTIOMER; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENE MUTATION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IDH1 GENE; IDH2 GENE; IN VIVO STUDY; LIMIT OF QUANTITATION; MOUSE; NONHUMAN; PHENOTYPE; TUMOR GROWTH; ANIMAL; DOUBLE STRANDED DNA BREAK; DRUG SCREENING; GENETICS; GLIOMA; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; FEMALE; GLIOMA; GLUTARATES; HOMOLOGOUS RECOMBINATION; HUMANS; ISOCITRATE DEHYDROGENASE; MICE, NUDE; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85012890102     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aal2463     Document Type: Article

References (71)

1. D. W. Parsons, S. Jones, X. Zhang, J. C.-H. Lin, R. J. Leary, P. Angenendt, P. Mankoo, H. Carter, I.-M. Siu, G. L. Gallia, A. Olivi, R. McLendon, B. A. Rasheed, S. Keir, T. Nikolskaya, Y. Nikolsky, D. A. Busam, H. Tekleab, L. A. Diaz Jr., J. Hartigan, D. R. Smith, R. L. Strausberg, S. K. N.Marie, S.M.O. Shinjo, H. Yan, G. J. Riggins, D. D. Bigner, R. Karchin, N. Papadopoulos, G. Parmigiani, B. Vogelstein, V. E. Velculescu, K. W. Kinzler, An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008).
2. E. R. Mardis, L. Ding, D. J. Dooling, D. E. Larson, M. D. McLellan, K. Chen, D. C. Koboldt, R. S. Fulton, K. D. Delehaunty, S. D. McGrath, L. A. Fulton, D. P. Locke, V. J. Magrini, R. M. Abbott, T. L. Vickery, J. S. Reed, J. S. Robinson, T. Wylie, S. M. Smith, L. Carmichael, J. M. Eldred, C. C. Harris, J. Walker, J. B. Peck, F. Du, A. F. Dukes, G. E. Sanderson, A. M. Brummett, E. Clark, J. F. McMichael, R. J. Meyer, J. K. Schindler, C. S. Pohl, J. W. Wallis, X. Shi, L. Lin, H. Schmidt, Y. Tang, C. Haipek, M. E. Wiechert, J. V. Ivy, J. Kalicki, G. Elliott, R. E. Ries, J. E. Payton, P. Westervelt, M. H. Tomasson, M. A. Watson, J. Baty, S. Heath, W. D. Shannon, R. Nagarajan, D. C. Link, M. J. Walter, T. A. Graubert, J. F. DiPersio, R. K. Wilson, T. J. Ley, Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058-1066 (2009).
3. H. Yan, D. W. Parsons, G. Jin, R. McLendon, B. A. Rasheed, W. Yuan, I. Kos, I. Batinic-Haberle, S. Jones, G. J. Riggins, H. Friedman, A. Friedman, D. Reardon, J. Herndon, K. W. Kinzler, V. E. Velculescu, B. Vogelstein, D. D. Bigner, IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773 (2009).
4. Y. Jiao, T. M. Pawlik, R. A. Anders, F. M. Selaru, M. M. Streppel, D. J. Lucas, N. Niknafs, V. B. Guthrie, A. Maitra, P. Argani, G. J. A. Offerhaus, J. C. Roa, L. R. Roberts, G. J. Gores, I. Popescu, S. T. Alexandrescu, S. Dima, M. Fassan, M. Simbolo, A. Mafficini, P. Capelli, R. T. Lawlor, A. Ruzzenente, A. Guglielmi, G. Tortora, F. de Braud, A. Scarpa, W. Jarnagin, D. Klimstra, R. Karchin, V. E. Velculescu, R. H. Hruban, B. Vogelstein, K.W. Kinzler, N. Papadopoulos, L. D. Wood, Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat. Genet. 45, 1470-1473 (2013).
5. M. Krauthammer, Y. Kong, B. H. Ha, P. Evans, A. Bacchiocchi, J. P. McCusker, E. Cheng, M. J. Davis, G. Goh, M. Choi, S. Ariyan, D. Narayan, K. Dutton-Regester, A. Capatana, E. C. Holman, M. Bosenberg, M. Sznol, H. M. Kluger, D. E. Brash, D. F. Stern, M. A. Materin, R. S. Lo, S. Mane, S. Ma, K. K. Kidd, N. K. Hayward, R. P. Lifton, J. Schlessinger, T. J. Boggon, R. Halaban, Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006-1014 (2012).
6. M. F. Amary, K. Bacsi, F. Maggiani, S. Damato, D. Halai, F. Berisha, R. Pollock, P. O'Donnell, A. Grigoriadis, T. Diss, M. Eskandarpour, N. Presneau, P. C. W. Hogendoorn, A. Futreal, R. Tirabosco, A. M. Flanagan, IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J. Pathol. 224, 334-343 (2011).
7. O. Clark, K. Yen, I. K. Mellinghoff, Molecular pathways: Isocitrate dehydrogenase mutations in cancer. Clin. Cancer Res. 22, 1837-1842 (2016).
8. L. Dang, D. W. White, S. Gross, B. D. Bennett, M. A. Bittinger, E. M. Driggers, V. R. Fantin, H. G. Jang, S. Jin, M. C. Keenan, K. M. Marks, R. M. Prins, P. S. Ward, K. E. Yen, L. M. Liau, J. D. Rabinowitz, L. C. Cantley, C. B. Thompson, M. G. Vander Heiden, S. M. Su, Cancerassociated IDH1 mutations produce 2-hydroxyglutarate. Nature 465, 966 (2010).
9. J.-A. Losman, W. G. Kaelin Jr., What a difference a hydroxyl makes: Mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 27, 836-852 (2013).
10. E.-H. Shim, C. B. Livi, D. Rakheja, J. Tan, D. Benson, V. Parekh, E.-Y. Kho, A. P. Ghosh, R. Kirkman, S. Velu, S. Dutta, B. Chenna, S. L. Rea, R. J. Mishur, Q. Li, T. L. Johnson-Pais, L. Guo, S. Bae, S. Wei, K. Block, S. Sudarshan, L-2-Hydroxyglutarate: An epigenetic modifier and putative oncometabolite in renal cancer. Cancer Discov. 4, 1290-1298 (2014).
11. A. M. Intlekofer, R. G. Dematteo, S. Venneti, L. W. S. Finley, C. Lu, A. R. Judkins, A. S. Rustenburg, P. B. Grinaway, J. D. Chodera, J. R. Cross, C. B. Thompson, Hypoxia induces production of L-2-hydroxyglutarate. Cell Metab. 22, 304-311 (2015).
12. W.M.Oldham, C. B. Clish, Y. Yang, J. Loscalzo, Hypoxia-mediatedincreases in L-2-hydroxyglutarate coordinate the metabolic response to reductive stress. Cell Metab. 22, 291-303 (2015).
13. W. Xu, H. Yang, Y. Liu, Y. Yang, P. Wang, S.-H. Kim, S. Ito, C. Yang, P. Wang, M.-T. Xiao, L.-x. Liu, W.-q. Jiang, J. Liu, J.-y. Zhang, B. Wang, S. Frye, Y. Zhang, Y.-h. Xu, Q.-y. Lei, K.-L. Guan, S.-m. Zhao, Y. Xiong, Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of a-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17-30 (2011).
14. A. Terunuma, N. Putluri, P. Mishra, E. A. Mathé, T. H. Dorsey, M. Yi, T. A. Wallace, H. J. Issaq, M. Zhou, J. K. Killian, H. S. Stevenson, E. D. Karoly, K. Chan, S. Samanta, D. Prieto, T. Y. T. Hsu, S. J. Kurley, V. Putluri, R. Sonavane, D. C. Edelman, J. Wulff, A. M. Starks, Y. Yang, R. A. Kittles, H. G. Yfantis, D. H. Lee, O. B. Ioffe, R. Schiff, R. M. Stephens, P. S. Meltzer, T. D. Veenstra, T. F. Westbrook, A. Sreekumar, S. Ambs, MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J. Clin. Invest. 124, 398-412 (2014).
15. K. Smolková, A. Dvořák, J. Zelenka, L. Vítek, P. Ježek, Reductive carboxylation and 2-hydroxyglutarate formation by wild-Type IDH2 in breast carcinoma cells. Int. J. Biochem. Cell Biol. 65, 125-133 (2015).
16. D. Rohle, J. Popovici-Muller, N. Palaskas, S. Turcan, C. Grommes, C. Campos, J. Tsoi, O. Clark, B. Oldrini, E. Komisopoulou, K. Kunii, A. Pedraza, S. Schalm, L. Silverman, A. Miller, F. Wang, H. Yang, Y. Chen, A. Kernytsky, M. K. Rosenblum, W. Liu, S. A. Biller, S. M. Su, C. W. Brennan, T. A. Chan, T. G. Graeber, K. E. Yen, I. K. Mellinghoff, An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340, 626-630 (2013).
17. +-dependent IDH activity in glioblastoma. Acta Neuropathol. 119, 487-494 (2010).
18. R. J. Molenaar, D. Verbaan, S. Lamba, C. Zanon, J. W. M. Jeuken, S. H. E. Boots-Sprenger, P. Wesseling, T. J. M. Hulsebos, D. Troost, A. A. van Tilborg, S. Leenstra, W. P. Vandertop, A. Bardelli, C. J. F. van Noorden, F. E. Bleeker, The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol. 16, 1263-1273 (2014).
19. P. Wang, Q. Dong, C. Zhang, P.-F. Kuan, Y. Liu, W. R. Jeck, J. B. Andersen, W. Jiang, G. L. Savich, T.-X. Tan, J. T. Auman, J. M. Hoskins, A. D. Misher, C. D. Moser, S. M. Yourstone, J. W. Kim, K. Cibulskis, G. Getz, H. V. Hunt, S. S. Thorgeirsson, L. R. Roberts, D. Ye, K.-L. Guan, Y. Xiong, L.-X. Qin, D. Y. Chiang, Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 32, 3091-3100 (2013).
20. A. N. Tran, A. Lai, S. Li, W. B. Pope, S. Teixeira, R. J. Harris, D. C. Woodworth, P. L. Nghiemphu, T. F. Cloughesy, B. M. Ellingson, Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. Neuro Oncol. 16, 414-420 (2014).
21. J. G. Cairncross, M. Wang, R. B. Jenkins, E. G. Shaw, C. Giannini, D. G. Brachman, J. C. Buckner, K. L. Fink, L. Souhami, N. J. Laperriere, J. T. Huse, M. P. Mehta, W. J. Curran, Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J. Clin. Oncol. 32, 783-790 (2014).
22. S. P. Jackson, T. Helleday, Drugging DNA repair. Science 352, 1178-1179 (2016).
23. J. Balss, S. Pusch, A.-C. Beck, C. Herold-Mende, A. Krämer, C. Thiede, W. Buckel, C.-D. Langhans, J. G. Okun, A. von Deimling, Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate. Acta Neuropathol. 124, 883-891 (2012).
24. + depletion. Cancer Cell 28, 773-784 (2015).
25. P. L. Olive, J. P. Banáth, The comet assay: A method to measure DNA damage in individual cells. Nat. Protoc. 1, 23-29 (2006).
26. B. L. Ruis, K. R. Fattah, E. A. Hendrickson, The catalytic subunit of DNA-dependent protein kinase regulates proliferation, telomere length, and genomic stability in human somatic cells. Mol. Cell. Biol. 28, 6182-6195 (2008).
27. I. Murfuni, G. Basile, S. Subramanyam, E. Malacaria, M. Bignami, M. Spies, A. Franchitto, P. Pichierri, Survival of the replication checkpoint deficient cells requires MUS81-RAD52 function. PLOS Genet. 9, e1003910 (2013).
28. J. R. Czochor, P. Sulkowski, P. M. Glazer, miR-155 overexpression promotes genomic instability by reducing high-fidelity polymerase delta expression and activating errorprone DSB repair. Mol. Cancer Res. 14, 363-373 (2016).
29. F. Fece de la Cruz, B. V. Gapp, S. M. B. Nijman, Synthetic lethal vulnerabilities of cancer. Annu. Rev. Pharmacol. Toxicol. 55, 513-531 (2015).
30. K. M. Foote, A. Lau, J. W. M. Nissink, Drugging ATR: Progress in the development of specific inhibitors for the treatment of cancer. Future Med. Chem. 7, 873-891 (2015).
31. A. G. Patel, J. N. Sarkaria, S. H. Kaufmann, Nonhomologous end joining drives poly(ADPribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc. Natl. Acad. Sci. U.S.A. 108, 3406-3411 (2011).
32. C. K. Donawho, Y. Luo, Y. Luo, T. D. Penning, J. L. Bauch, J. J. Bouska, V. D. Bontcheva-Diaz, B. F. Cox, T. L. DeWeese, L. E. Dillehay, D. C. Ferguson, N. S. Ghoreishi-Haack, D. R. Grimm, R. Guan, E. K. Han, R. R. Holley-Shanks, B. Hristov, K. B. Idler, K. Jarvis, E. F. Johnson, L. R. Kleinberg, V. Klinghofer, L. M. Lasko, X. Liu, K. C. Marsh, T. P. McGonigal, J. A. Meulbroek, A. M. Olson, J. P. Palma, L. E. Rodriguez, Y. Shi, J. A. Stavropoulos, A. C. Tsurutani, G.-D. Zhu, S. H. Rosenberg, V. L. Giranda, D. J. Frost, ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res. 13, 2728-2737 (2007).
33. U. Kortmann, J. N. McAlpine, H. Xue, J. Guan, G. Ha, S. Tully, S. Shafait, A. Lau, A. N. Cranston, M. J. O'Connor, D. G. Huntsman, Y. Wang, C. B. Gilks, Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin. Cancer Res. 17, 783-791 (2011).
34. J.-M. Lee, J. L. Hays, C. M. Annunziata, A. M. Noonan, L. Minasian, J. A. Zujewski, M. Yu, N. Gordon, J. Ji, T. M. Sissung, W. D. Figg, N. Azad, B. J. Wood, J. Doroshow, E. C. Kohn, Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-Associated breast or ovarian cancer with biomarker analyses. J. Natl. Cancer Inst. 106, dju089 (2014).
35. A. M. Oza, D. Cibula, A. O. Benzaquen, C. Poole, R. H. J. Mathijssen, G. S. Sonke, N. Colombo, J. Špaček, P. Vuylsteke, H. Hirte, S. Mahner, M. Plante, B. Schmalfeldt, H. Mackay, J. Rowbottom, E. S. Lowe, B. Dougherty, J. C. Barrett, M. Friedlander, Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncol. 16, 87-97 (2015).
36. G. Y. Di Veroli, C. Fornari, D. Wang, S. Mollard, J. L. Bramhall, F. M. Richards, D. I. Jodrell, Combenefit: An interactive platform for the analysis and visualization of drug combinations. Bioinformatics 32, 2866-2868 (2016).
37. A. J. Pierce, R. D. Johnson, L. H. Thompson, M. Jasin, XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev. 13, 2633-2638 (1999).
38. E. Baader, G. Tschank, K. H. Baringhaus, H. Burghard, V. Günzler, Inhibition of prolyl 4-hydroxylase by oxalyl amino acid derivatives in vitro, in isolated microsomes and in embryonic chicken tissues. Biochem. J. 300 (Pt. 2), 525-530 (1994).
39. A. G. Goglia, R. Delsite, A. N. Luz, D. Shahbazian, A. F. Salem, R. K. Sundaram, J. Chiaravalli, P. J. Hendrikx, J. A. Wilshire, M. Jasin, H. M. Kluger, J. F. Glickman, S. N. Powell, R. S. Bindra, Identification of novel radiosensitizers in a high-Throughput, cell-based screen for DSB repair inhibitors. Mol. Cancer Ther. 14, 326-342 (2015).
40. L.-Y. Wang, C.-L. Hung, Y.-R. Chen, J. C. Yang, J. Wang, M. Campbell, Y. Izumiya, H.-W. Chen, W.-C. Wang, D. K. Ann, H.-J. Kung, KDM4A coactivates E2F1 to regulate the PDK-dependent metabolic switch between mitochondrial oxidation and glycolysis. Cell Rep. 16, 3016-3027 (2016).
41. C.-H. Chu, L.-Y. Wang, K.-C. Hsu, C.-C. Chen, H.-H. Cheng, S.-M. Wang, C.-M. Wu, T.-J. Chen, L.-T. Li, R. Liu, C.-L. Hung, J.-M. Yang, H.-J. Kung, W.-C. Wang, KDM4B as a target forprostate cancer: Structural analysis and selective inhibition by a novel inhibitor. J. Med. Chem. 57, 5975-5985 (2014).
42. F. A. Mallette, F. Mattiroli, G. Cui, L. C. Young, M. J. Hendzel, G. Mer, T. K. Sixma, S. Richard, RNF8-And RNF168-dependent degradation of KDM4A/JMJD2A triggers 53BP1 recruitment to DNA damage sites. EMBO J. 31, 1865-1878 (2012).
43. L. C. Young, D. W. McDonald, M. J. Hendzel, Kdm4b histone demethylase is a DNA damage response protein and confers a survival advantage following g-irradiation. J. Biol. Chem. 288, 21376-21388 (2013).
44. L. Li, A. C. Paz, B. A. Wilky, B. Johnson, K. Galoian, A. Rosenberg, G. Hu, G. Tinoco, O. Bodamer, J. C. Trent, Treatment with a small molecule mutant IDH1 inhibitor suppresses tumorigenic activity and decreases production of the oncometabolite 2-hydroxyglutarate in human chondrosarcoma cells. PLOS ONE 10, e0133813 (2015).
45. + depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death. J. Neurosci. 30, 2967-2978 (2010).
46. H.-Q. Ju, Z.-N. Zhuang, H. Li, T. Tian, Y.-X. Lu, X.-Q. Fan, H.-J. Zhou, H.-Y. Mo, H. Sheng, P. J. Chiao, R.-H. Xu, Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer. Cancer Lett. 379, 1-11 (2016).
47. H. Bai, A. S. Harmanci, E. Z. Erson-Omay, J. Li, S. Coskun, M. Simon, B. Krischek, K. Özduman, S. B. Omay, E. A. Sorensen, S. Turcan, M. Bakirciǧlu, G. Carrión-Grant, P. B. Murray, V. E. Clark, A. G. Ercan-Sencicek, J. Knight, L. Sencar, S. Altinok, L. D. Kaulen, B. Gülez, M. Timmer, J. Schramm, K. Mishra-Gorur, O. Henegariu, J. Moliterno, A. Louvi, T. A. Chan, S. L. Tannheimer, M. N. Pamir, A. O. Vortmeyer, K. Bilguvar, K. Yasuno, M. Günel, Integrated genomic characterization of IDH1-mutant glioma malignant progression. Nat. Genet. 48, 59-66 (2016).
48. Y. Lu, A. Chu, M. S. Turker, P. M. Glazer, Hypoxia-induced epigenetic regulation and silencing of the BRCA1 promoter. Mol. Cell. Biol. 31, 3339-3350 (2011).
49. R. S. Bindra, P. M. Glazer, Basal repression of BRCA1 by multiple E2Fs and pocket proteins at adjacent E2F sites. Cancer Biol. Ther. 5, 1400-1407 (2006).
50. S. E. Scanlon, P. M. Glazer, Hypoxic stress facilitates acute activation and chronic downregulation of fanconi anemia proteins. Mol. Cancer Res. 12, 1016-1028 (2014).
51. J. Mondesir, C. Willekens, M. Touat, S. de Botton, IDH1 and IDH2 mutations as novel therapeutic targets: Current perspectives. J. Blood Med. 7, 171-180 (2016).
52. S. Babakoohi, R. G. Lapidus, R. Faramand, E. A. Sausville, A. Emadi, Comparative analysis of methods for detecting isocitrate dehydrogenase 1 and 2 mutations and their metabolic consequence, 2-hydroxyglutarate, in different neoplasms. Appl. Immunohistochem. Mol. Morphol. 10.1097/PAI.0000000000000342 (2016).
53. U. E. Emir, S. J. Larkin, N. de Pennington, N. Voets, P. Plaha, R. Stacey, K. Al-Qahtani, J. Mccullagh, C. J. Schofield, S. Clare, P. Jezzard, T. Cadoux-Hudson, O. Ansorge, Noninvasive quantification of 2-hydroxyglutarate in human gliomas with IDH1 and IDH2 mutations. Cancer Res. 76, 43-49 (2016).
54. A. J. Chalmers, A. Jackson, H. Swaisland, W. Stewart, S. E. R. Halford, L. R. Molife, D. R. Hargrave, A. McCormick, Results of stage 1 of the oparatic trial: A phase I study of olaparib in combination with temozolomide in patients with relapsed glioblastoma. J. Clin. Oncol. 32, abstract 2025 (2014).
55. J. M. Su, P. Thompson, A. Adesina, X.-N. Li, L. Kilburn, A. Onar-Thomas, M. Kocak, B. Chyla, E. McKeegan, K. E. Warren, S. Goldman, I. F. Pollack, M. Fouladi, A. Chen, V. Giranda, J. Boyett, L. Kun, S. M. Blaney, A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: A pediatric brain tumor consortium report. Neuro. Oncol. 16, 1661-1668 (2014).
56. J. A. Muscal, P. A. Thompson, V. L. Giranda, B. D. Dayton, J. Bauch, T. Horton, L. McGuffey, J. G. Nuchtern, R. C. Dauser, B. W. Gibson, S. M. Blaney, J. M. Su, Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. Cancer Chemother. Pharmacol. 65, 419-425 (2010).
57. S. Gross, R. Rahal, N. Stransky, C. Lengauer, K. P. Hoeflich, Targeting cancer with kinase inhibitors. J. Clin. Invest. 125, 1780-1789 (2015).
58. L. Dang, K. Yen, E. C. Attar, IDH mutations in cancer and progress toward development of targeted therapeutics. Ann. Oncol. 27, 599-608 (2016).
59. B. M. Gyori, G. Venkatachalam, P. S. Thiagarajan, D. Hsu, M.-V. Clement, OpenComet: An automated tool for comet assay image analysis. Redox Biol. 2, 457-465 (2014).
60. G. Chatterjee, J. Jimenez-Sainz, T. Presti, T. Nguyen, R. B. Jensen, Distinct binding of BRCA2 BRC repeats to RAD51 generates differential DNA damage sensitivity. Nucleic Acids Res. 44, 5256-5270 (2016).
61. J. Zhuang, J. Zhang, H. Willers, H. Wang, J. H. Chung, D. C. van Gent, D. E. Hallahan, S. N. Powell, F. Xia, Checkpoint kinase 2-mediated phosphorylation of BRCA1 regulates the fidelity of nonhomologous end-joining. Cancer Res. 66, 1401-1408 (2006).
62. G. C. Stachelek, E. Peterson-Roth, Y. Liu, R. J. Fernandez III, L. R. G. Pike, J. M. Qian, L. Abriola, D. Hoyer, W. Hungerford, J. Merkel, P. M. Glazer, YU238259 is a novel inhibitor of homology-dependent DNA repair that exhibits synthetic lethality and radiosensitization in repair-deficient tumors. Mol. Cancer Res. 13, 1389-1397 (2015).
63. R. S. Bindra, A. G. Goglia, M. Jasin, S. N. Powell, Development of an assay to measure mutagenic non-homologous end-joining repair activity in mammalian cells. Nucleic Acids Res. 41, e115 (2013).
64. K. Nakanishi, Y.-G. Yang, A. J. Pierce, T. Taniguchi, M. Digweed, A. D. D'Andrea, Z.-Q. Wang, M. Jasin, Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. Proc. Natl. Acad. Sci. U.S.A. 102, 1110-1115 (2005).
65. W. Sakai, E. M. Swisher, C. Jacquemont, K. V. Chandramohan, F. J. Couch, S. P. Langdon, K. Wurz, J. Higgins, E. Villegas, T. Taniguchi, Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res. 69, 6381-6386 (2009).
66. B. K. Singleton, A. Priestley, H. Steingrimsdottir, D. Gell, T. Blunt, S. P. Jackson, A. R. Lehmann, P. A. Jeggo, Molecular and biochemical characterization of xrs mutants defective in Ku80. Mol. Cell. Biol. 17, 1264-1273 (1997).
67. S. M. Chan, D. Thomas, M. R. Corces-Zimmerman, S. Xavy, S. Rastogi, W.-J. Hong, F. Zhao, B. C. Medeiros, D. A. Tyvoll, R. Majeti, Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat. Med. 21, 178-184 (2015).
68. S. Turcan, D. Rohle, A. Goenka, L. A. Walsh, F. Fang, E. Yilmaz, C. Campos, A. W. M. Fabius, C. Lu, P. S. Ward, C. B. Thompson, A. Kaufman, O. Guryanova, R. Levine, A. Heguy, A. Viale, L. G. T. Morris, J. T. Huse, I. K. Mellinghoff, T. A. Chan, IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483, 479-483 (2012).
69. C. A. Lewis, S. J. Parker, B. P. Fiske, D. McCloskey, D. Y. Gui, C. R. Green, N. I. Vokes, A.M. Feist, M. G. Vander Heiden, C.M.Metallo, Tracing compartmentalized NADPHmetabolism in the cytosol and mitochondria of mammalian cells. Mol. Cell 55, 253-263 (2014).
70. Y. V. Surovtseva, V. Jairam, A. F. Salem, R. K. Sundaram, R. S. Bindra, S. B. Herzon, Characterization of cardiac glycoside natural products as potent inhibitors of DNA double-strand break repair by a whole-cell double immunofluorescence assay. J. Am. Chem. Soc. 138, 3844-3855 (2016).
71. G. M. I. Chowdhury, L. Jiang, D. L. Rothman, K. L. Behar, The contribution of ketone bodies to basal and activity-dependent neuronal oxidation in vivo. J. Cereb. Blood Flow Metab. 34, 1233-1242 (2014).